JP2011518881A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518881A5 JP2011518881A5 JP2011507418A JP2011507418A JP2011518881A5 JP 2011518881 A5 JP2011518881 A5 JP 2011518881A5 JP 2011507418 A JP2011507418 A JP 2011507418A JP 2011507418 A JP2011507418 A JP 2011507418A JP 2011518881 A5 JP2011518881 A5 JP 2011518881A5
- Authority
- JP
- Japan
- Prior art keywords
- limited
- drug
- acid
- group
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 16
- 229940079593 drugs Drugs 0.000 claims 16
- -1 crystal Substances 0.000 claims 9
- 239000000969 carrier Substances 0.000 claims 5
- 208000006561 Cluster Headache Diseases 0.000 claims 4
- 229920002307 Dextran Polymers 0.000 claims 4
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 4
- 229960004503 metoclopramide Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims 3
- FGXWKSZFVQUSTL-UHFFFAOYSA-N Domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims 3
- OTLDLQZJRFYOJR-LJQANCHMSA-N Eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims 3
- 206010027599 Migraine Diseases 0.000 claims 3
- 208000008085 Migraine Disorders Diseases 0.000 claims 3
- 206010027603 Migraine headache Diseases 0.000 claims 3
- UNHGSHHVDNGCFN-UHFFFAOYSA-N Naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims 3
- TXHZXHICDBAVJW-UHFFFAOYSA-N Rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims 3
- 229960003708 Sumatriptan Drugs 0.000 claims 3
- GKZARTFJSANTLY-UHFFFAOYSA-N Sumatriptan Chemical compound [CH]1C(CS(=O)(=O)NC)=CC=C2N=CC(CCN(C)C)=C21 GKZARTFJSANTLY-UHFFFAOYSA-N 0.000 claims 3
- 229960002133 almotriptan Drugs 0.000 claims 3
- 229960001253 domperidone Drugs 0.000 claims 3
- 229960002472 eletriptan Drugs 0.000 claims 3
- 230000000051 modifying Effects 0.000 claims 3
- 229960005254 naratriptan Drugs 0.000 claims 3
- 229960000425 rizatriptan Drugs 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 claims 3
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 3
- 229920001661 Chitosan Polymers 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 claims 2
- SIBNYOSJIXCDRI-SECBINFHSA-N Frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N Methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims 2
- 229960005343 Ondansetron Drugs 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 229920002732 Polyanhydride Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 229920001710 Polyorthoester Polymers 0.000 claims 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N Prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 229960005188 collagen Drugs 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000000412 dendrimer Substances 0.000 claims 2
- 229920000736 dendritic polymer Polymers 0.000 claims 2
- 229960003413 dolasetron Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229960002284 frovatriptan Drugs 0.000 claims 2
- 229910003472 fullerene Inorganic materials 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 229960004662 parecoxib Drugs 0.000 claims 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims 2
- 239000002745 poly(ortho ester) Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000004633 polyglycolic acid Substances 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 229960003111 prochlorperazine Drugs 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 235000000346 sugar Nutrition 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 claims 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 2
- ZFKBWSREWJOSSJ-VIFPVBQESA-N (2S)-6,8-dichloro-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid Chemical compound ClC1=CC(Cl)=C2O[C@H](C(F)(F)F)C(C(=O)O)=CC2=C1 ZFKBWSREWJOSSJ-VIFPVBQESA-N 0.000 claims 1
- XNTLXAUHLBBEKP-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound O=C1C(OCCC(C)(O)C)=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=NN1C1=CC=C(F)C(F)=C1 XNTLXAUHLBBEKP-UHFFFAOYSA-N 0.000 claims 1
- OKGJGFZQNSWNSS-UHFFFAOYSA-N 2-[2-(2,4-dichloro-6-methylanilino)-5-ethylphenyl]acetic acid Chemical compound OC(=O)CC1=CC(CC)=CC=C1NC1=C(C)C=C(Cl)C=C1Cl OKGJGFZQNSWNSS-UHFFFAOYSA-N 0.000 claims 1
- VALVBSGRQKSVKH-UHFFFAOYSA-N 3-(4-cyclohexyl-2-methyl-1,3-oxazol-5-yl)-2-fluorobenzenesulfonamide Chemical compound C=1C=CC(S(N)(=O)=O)=C(F)C=1C=1OC(C)=NC=1C1CCCCC1 VALVBSGRQKSVKH-UHFFFAOYSA-N 0.000 claims 1
- KQPKPCNLIDLUMF-MRVPVSSYSA-N 5-[(2R)-pentan-2-yl]-5-prop-2-enyl-1,3-diazinane-2,4,6-trione Chemical compound CCC[C@@H](C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-MRVPVSSYSA-N 0.000 claims 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 1
- 229940022659 Acetaminophen Drugs 0.000 claims 1
- LGGDXXJAGWBUSL-BKRJIHRRSA-N Acetyldihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](OC(C)=O)[C@@H]1OC1=C2C3=CC=C1OC LGGDXXJAGWBUSL-BKRJIHRRSA-N 0.000 claims 1
- 229960001391 Alfentanil Drugs 0.000 claims 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N Alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims 1
- 229960001301 Amobarbital Drugs 0.000 claims 1
- VIROVYVQCGLCII-UHFFFAOYSA-N Amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 claims 1
- JSZILQVIPPROJI-UHFFFAOYSA-N Benzquinamide Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(C(=O)N(CC)CC)C(OC(C)=O)C2 JSZILQVIPPROJI-UHFFFAOYSA-N 0.000 claims 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K Bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims 1
- 108010043024 Botulinum Toxins Proteins 0.000 claims 1
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 claims 1
- 102100006973 CYSLTR1 Human genes 0.000 claims 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001076 Chlorpromazine Drugs 0.000 claims 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N Cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 claims 1
- 229960000876 Cinnarizine Drugs 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 102000016736 Cyclins Human genes 0.000 claims 1
- 108050006400 Cyclins Proteins 0.000 claims 1
- WTYGAUXICFETTC-UHFFFAOYSA-N Cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 claims 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N Deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 claims 1
- FDQGNLOWMMVRQL-UHFFFAOYSA-N Diadol Chemical compound C=CCC1(CC=C)C(=O)NC(=O)NC1=O FDQGNLOWMMVRQL-UHFFFAOYSA-N 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N Dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N Dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims 1
- 229960004993 Dimenhydrinate Drugs 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N Diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 claims 1
- 206010013496 Disturbance in attention Diseases 0.000 claims 1
- 208000002173 Dizziness Diseases 0.000 claims 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N Droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims 1
- 229960000394 Droperidol Drugs 0.000 claims 1
- 229940089114 Drug Delivery Device Drugs 0.000 claims 1
- 229960004943 Ergotamine Drugs 0.000 claims 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N Ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims 1
- 229960003976 Etidocaine Drugs 0.000 claims 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- 241001539473 Euphoria Species 0.000 claims 1
- 206010015535 Euphoric mood Diseases 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 Fentanyl Drugs 0.000 claims 1
- 206010016807 Fluid retention Diseases 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 230000036328 Free drug Effects 0.000 claims 1
- MBPTXJNHCBXMBP-SDIIOJARSA-N Galanolactone Chemical compound C([C@@H]1[C@@]2(C)CCCC([C@@H]2CC[C@]11OC1)(C)C)\C=C1/CCOC1=O MBPTXJNHCBXMBP-SDIIOJARSA-N 0.000 claims 1
- MBPTXJNHCBXMBP-PWSCQACJSA-N Galanolactone Natural products O=C1/C(=C\C[C@@H]2[C@@]3(C)[C@H](C(C)(C)CCC3)CC[C@@]32OC3)/CCO1 MBPTXJNHCBXMBP-PWSCQACJSA-N 0.000 claims 1
- 229940014259 Gelatin Drugs 0.000 claims 1
- 229960003727 Granisetron Drugs 0.000 claims 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 1
- 206010019233 Headache Diseases 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N Hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 108090000862 Ion Channels Proteins 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims 1
- XVQUOJBERHHONY-UHFFFAOYSA-N Isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 claims 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 1
- 229960005015 Local anesthetics Drugs 0.000 claims 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 claims 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 claims 1
- 101710034449 MT-CO2 Proteins 0.000 claims 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims 1
- 229940041321 Meclizine Drugs 0.000 claims 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 1
- ALARQZQTBTVLJV-UHFFFAOYSA-N Methylphenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 claims 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N Methysergide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 claims 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- GECBBEABIDMGGL-RTBURBONSA-N Nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001597 Nifedipine Drugs 0.000 claims 1
- 229940005483 OPIOID ANALGESICS Drugs 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 101710040930 PTGS2 Proteins 0.000 claims 1
- 206010033474 Pain of skin Diseases 0.000 claims 1
- 206010033546 Pallor Diseases 0.000 claims 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N Palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 1
- XQYZDYMELSJDRZ-UHFFFAOYSA-N Papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 229960001412 Pentobarbital Drugs 0.000 claims 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000762 Perphenazine Drugs 0.000 claims 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002695 Phenobarbital Drugs 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims 1
- 229950000688 Phenothiazine Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N Prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 229960003394 Remifentanil Drugs 0.000 claims 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims 1
- GZSKEXSLDPEFPT-IINYFYTJSA-N Renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 claims 1
- 229950003039 Renzapride Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
- 210000002832 Shoulder Anatomy 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 229960004739 Sufentanil Drugs 0.000 claims 1
- 102100009263 TRPV1 Human genes 0.000 claims 1
- 108060008565 TRPV1 Proteins 0.000 claims 1
- 229960002372 Tetracaine Drugs 0.000 claims 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 claims 1
- XCTYLCDETUVOIP-UHFFFAOYSA-N Thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 claims 1
- 229960004869 Thiethylperazine Drugs 0.000 claims 1
- 206010043458 Thirst Diseases 0.000 claims 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N Tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims 1
- 229960004380 Tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N Tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Tranquisan Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 1
- 229960002324 Trifluoperazine Drugs 0.000 claims 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N Trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 1
- 229960003904 Triflupromazine Drugs 0.000 claims 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N Triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims 1
- 240000005216 Trigonella foenum-graecum Species 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- KGKJZEKQJQQOTD-UHFFFAOYSA-N Vinylbital Chemical compound CCCC(C)C1(C=C)C(=O)NC(=O)NC1=O KGKJZEKQJQQOTD-UHFFFAOYSA-N 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 229960002948 acetyldihydrocodeine Drugs 0.000 claims 1
- 229960000880 allobarbital Drugs 0.000 claims 1
- 229960003550 alosetron Drugs 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 229960004564 benzquinamide Drugs 0.000 claims 1
- 229960000782 bismuth subsalicylate Drugs 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims 1
- 229960005132 cisapride Drugs 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 229960004138 cyclobarbital Drugs 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 229960003314 deracoxib Drugs 0.000 claims 1
- 229960002086 dextran Drugs 0.000 claims 1
- 201000008286 diarrhea Diseases 0.000 claims 1
- 229960003529 diazepam Drugs 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960004704 dihydroergotamine Drugs 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- 229960000520 diphenhydramine Drugs 0.000 claims 1
- 229960003520 diphenidol Drugs 0.000 claims 1
- 229960004242 dronabinol Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- XCGSFFUVFURLIX-VFGNJEKYSA-O ergopeptine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1C[NH+]([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-O 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- 230000001815 facial Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- 229960000930 hydroxyzine Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960002672 isocarboxazid Drugs 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 229960003046 isometheptene Drugs 0.000 claims 1
- 229960003299 ketamine Drugs 0.000 claims 1
- 108010002279 leukotriene D4 receptor Proteins 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 239000004973 liquid crystal related substance Substances 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 claims 1
- 229960004391 lorazepam Drugs 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 229960003803 meclofenamic acid Drugs 0.000 claims 1
- 229960001474 meclozine Drugs 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- 230000003340 mental Effects 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 1
- 229960001703 methylphenobarbital Drugs 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 229960001186 methysergide Drugs 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229930014694 morphine Natural products 0.000 claims 1
- 229960002967 nabilone Drugs 0.000 claims 1
- 239000002159 nanocrystal Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 239000000014 opioid analgesic Substances 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 229960002131 palonosetron Drugs 0.000 claims 1
- 229960001789 papaverine Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229950010883 phencyclidine Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- 102000004257 potassium channel family Human genes 0.000 claims 1
- 108020001213 potassium channel family Proteins 0.000 claims 1
- 229960001807 prilocaine Drugs 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 229960003910 promethazine Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960002646 scopolamine Drugs 0.000 claims 1
- 229960002060 secobarbital Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000003890 substance P antagonist Substances 0.000 claims 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
- 229960003688 tropisetron Drugs 0.000 claims 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- 229960005392 vinylbital Drugs 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N γ-lactone 4-hydroxy-butyric acid Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims 1
Claims (15)
- 薬物送達システムと、
1時間またはそれ未満のうちに即効性の疼痛軽減効果を提供する第1の成分および4時間を越える期間にわたって長期の疼痛軽減効果を提供する第2の成分を含む二相製剤と
を含む、片頭痛または群発頭痛を治療するためのシステム。 - 第1の成分が第1の薬物を含み、かつ第2の成分が第1の薬物と異なる第2の薬物を含む、請求項1記載のシステム。
- 第1の薬物が、スマトリプタン、アルモトリプタン、エレトリプタン、リザトリプタン、およびゾミトリプタン(zomitriptan)からなる群より選択され、かつ第2の薬物が、ナラトリプタン、フロバトリプタンからなる群より選択される、請求項1記載のシステム。
- 薬物送達システムが無針注射器であり、かつ第2の成分が、トリプタンと、4時間またはそれ以上の期間にわたって該トリプタンの制御放出を提供する担体とからなる、請求項1記載のシステム。
- 担体が、ポリ(オルトエステル)、ポリ乳酸、ポリグリコール酸、乳酸、グリコール酸、メタクラレート(methacralate)、カプロラクトン、キトサン、ポリ酸無水物、ポリエチレングリコール、ポリホスホエステル(polyphosphoester)、ポリホスホスファゼン(polyphosphosphazene)、デキストラン、炭水化物、糖、デンドリマー、星型ポリマー、フラーレン、リポソームを含むがこれに限定されないポリマーハイブリッドを伴うかまたは伴わない脂質の物理的凝集物、ポリエーテルエステル、ヒアルロン酸、コラーゲ(collage)、ゼラチン、デキストラン、両親媒性物質、メタクリルアミド、ポリエチレンオキシド、それらのコポリマーおよび複合物からなる群より選択され、かつ第2の成分が1,000 cPまたはそれ以上の粘性を有し、かつ第2の成分が10,000 cPまたはそれ以上の粘性を有し、かつさらに薬物送達システムが無針注射器である、請求項4記載のシステム。
- 第1の成分が遊離薬物からなり、かつ第2の成分が制御放出担体中に含まれる薬物からなり、かつ第2の成分が、コロイド、懸濁液、結晶、ナノ結晶、粒子、ナノ粒子、乳濁液、ゲル、液晶、および溶液からなる群より選択される形態である、請求項1記載のシステム。
- 薬物送達システムが無針注射器であり、製剤が高粘性を有し、かつ制御放出担体が、ポリ(オルトエステル)、ポリ乳酸、ポリグリコール酸、乳酸、グリコール酸、メタクラレート(methacralate)、カプロラクトン、キトサン、ポリ酸無水物、ポリエチレングリコール、ポリホスホエステル(polyphosphoester)、ポリホスホスファゼン(polyphosphosphazene)、デキストラン、炭水化物、糖、デンドリマー、星型ポリマー、フラーレン、リポソームを含むがこれに限定されないポリマーハイブリッドを伴うかまたは伴わない脂質の物理的凝集物、ポリエーテルエステル、ヒアルロン酸、コラーゲ(collage)、ゼラチン、デキストラン、両親媒性物質、メタクリルアミド、ポリエチレンオキシド、それらのコポリマーおよび複合物からなる群より選択され、かつ第2の成分が1,000 cPまたはそれ以上の粘性を有する、請求項6記載のシステム。
- 注射の際に、注射液の担体が、薬物の周囲にデポーを形成する、請求項7記載のシステム。
- 製剤が、スマトリプタン、アルモトリプタン、エレトリプタン、フロバトリプタン、ナラトリプタン、リザトリプタン、ゾミトリプタンを含むがこれらに限定されないトリプタン;エルゴタミン、メチセルジド、ジヒドロエルゴタミンを含むがこれらに限定されないエルゴペプチン(Ergopeptine);アスピリン、イブプロフェン、ナプロキセン、アセトアミノフェン、ジクロフェナク、フルルビプロフェン、メクロフェナム酸、イソメテプテン インドメタシンを含むがこれらに限定されないNSAID;コデイン、モルヒネ、ヒドロコドン、アセチルジヒドロコデイン、オキシコドン、オキシモルフォン、パパベリン、フェンタニル、アルフェンタニル、スフェンタニル、レミフェンタニル、トラマドールを含むがこれらに限定されないオピオイド鎮痛剤;プロクロルペラジンを含むがこれに限定されないフェノチアジン;セレコキシブ、ロフェコキシブ、メロキシカム、ピロキシカム、JTE-522、L-745,337、NS398、デラコキシブ(deracoxib)、バルデコキシブ、イウミラコキシブ(iumiracoxib)、エトリコキシブ、パレコキシブ、4-(4-シクロヘキシル-2-メチルオキサゾール-5-イル)-2フルオロベンゼンスルホンアミド、2-(3,5-ジフルオロフェニル)-3-(4-(メチルスルホニル)フェニル)-2シクロペンテン-1-オン、N-[2-(シクロヘキシルオキシ)-4-ニトロフェニル]メタンスルホンアミド、2-(3,4ジフルオロフェニル)-4-(3-ヒドロキシ-3-メチルブトキシ)-5-[4-(メチルスルホニル)フェニル]-3(2H)ピリダジノン、2-[(2,4-ジクロロ-6-メチルフェニル)アミノ]-5-エチル-ベンゼン酢酸、(3Z) 3-[(4-クロロフェニル)[4-(メチルスルホニル)フェニル]メチレン]ジヒドロ-2(3H)-フラノン、および(S)-6,8-ジクロロ-2-(トリフルオロメチル)-2H-1-ベンゾピラン-3-カルボン酸を含むがこれらに限定されないCox-2阻害剤;アモバルビタール、ブタルビタール、シクロバルビタール、ペントバルビタール、アロバルビタール、メチルフェノバルビタール、フェノバルビタール、セコバルビタール、ビニルビタールを含むがこれらに限定されないバルビツレート;ナトリウムチャネルモジュレーター、カリウムチャネルモジュレーターを含むがこれらに限定されないイオンチャネルモジュレーター;ベラパミル、ジルチアゼム、ニフェジピンを含むがこれらに限定されないカルシウムチャネル遮断剤;リドカイン、テトラカイン、プリロカイン、ブピビカイン(bupivicaine)、メピバカイン、エチドカイン、プロカイン、ベンゾカインを含むがこれらに限定されない局所麻酔剤;フェヘルジン(phehelzine)、イソカルボキサジドを含むがこれらに限定されないモノアミン酸化酵素阻害剤;ロイコトリエンLTD4受容体遮断剤、ジクロラルフェナゾン、ニモピジン(nimopidine)、メトクロプラミド、カプサイシン受容体アゴニスト、ボツリヌス毒素、カプトプリル、チオスピロン(tiospirone)、ステロイド、カフェイン、メトクロプラミド、ドンペリドン、スコポラミン、ジメンヒドリナート、ジフェンヒドラミン、ヒドロキシジン、ジアゼパム、ロラゼパム、クロルプロマジン、メトトリメプラジン、ペルフェナジン、プロクロルペラジン、プロメタジン、トリフルオペラジン、トリフルプロマジン、ベンズキナミド、次サリチル酸ビスマス、ブクリジン、シンナリジン、シクリジン、ジフェニドール、ドラセトロン、ドンペリドン、ドロナビノール、ドロペリドール、ハロペリドール、メトクロプラミド、ナビロン、チエチルペラジン、トリメトベンゼミド(trimethobenzemide)、およびエジオピタント(eziopitant)、メクリジン、またはサブスタンスPアンタゴニスト、ドンペリドン;オンダンセトロン、トロピセトロン グラニセトロン ドラセトロン、ヒドロドラセトロン(hydrodolasetron)、パロノセトロン、アロセトロン、シランセトロン、シサプリド、レンザプリド(renzapride) メトクロプラミド、ガラノラクトン(galanolactone)を含むがこれらに限定されない5-HT3アンタゴニスト;フェンシクリジン、ケタミン、デキストロメトルファンを含むがこれらに限定されないNMDAアンタゴニスト、ならびにそれらの異性体、薬学的に許容される塩、エステル、またはプロドラッグからなる群より選択される薬物を含む、請求項1記載のシステム。
- 薬物送達装置と、
片頭痛または群発頭痛の第1の症状を治療するための第1の薬学的に活性な薬物と、
第1の症状とは異なる片頭痛または群発頭痛の第2の症状を治療するための第2の薬学的に活性な薬物と
を含む、片頭痛または群発頭痛を治療するためのシステム。 - 第1の症状が疼痛であり、かつ
第2の症状が、
肩こり、悪寒、脱力感、眩暈、口渇増加、排尿増加、下痢、便秘、体液貯留、食物への欲求、光に対する感受性、音に対する感受性、疲労、眠気、食欲不振、嘔気、嘔吐、臭気に対する感受性、視界不良、鼻詰まり、顔面蒼白、熱感 冷感、発汗、頭皮の圧痛、静脈の隆起、動脈の隆起、液小嚢(small pocket of fluid)の蓄積、集中力の低下、神経過敏;抑鬱、多幸感、易刺激性、不隠状態、精神機能低下、活動亢進を含むがこれらに限定されない心理的症状;閃輝暗点、物体の視覚的なサイズ変更もしくは形状変更、体の片側での顔、腕、もしくは手のしびれもしくは刺痛、筋力低下、体の片側での軽度麻痺、発話困難、または失語(loss of speech)を含むがこれらに限定されない前兆症状
からなる群より選択される、
請求項10記載のシステム。 - 第1の薬学的に活性な薬物が5-HT1アゴニストであり、かつ第2の薬学的に活性な薬物が5-HT3アンタゴニストである、請求項10記載のシステム。
- 5-HT1アゴニストがトリプタンである、請求項12記載のシステム。
- 5-HT1アゴニストが、スマトリプタン、アルモトリプタン、エレトリプタン、フロバトリプタン、ナラトリプタン、リザトリプタン、ゾミトリプタン、それらの薬学的に許容される塩、異性体、類似体からなる群より選択される、請求項12記載のシステム。
- 5-HT3アンタゴニストが、オンダンセトロン、トロピセトロン、グラニセトロン、ドラセトロン、ヒドロドラセトロン、パロノセトロン、アロセトロン、シランセトロン、シサプリド、レンザプリド、メトクロプラミド、ガラノラクトン、またはこれらの組み合わせからなる群より選択される、請求項12記載のシステム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4846308P | 2008-04-28 | 2008-04-28 | |
US61/048,463 | 2008-04-28 | ||
PCT/US2009/002533 WO2009134336A1 (en) | 2008-04-28 | 2009-04-24 | Novel formulations for treatment of migraine |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014020406A Division JP5943948B2 (ja) | 2008-04-28 | 2014-02-05 | 片頭痛の治療のための製剤 |
JP2015054395A Division JP2015178496A (ja) | 2008-04-28 | 2015-03-18 | 片頭痛の治療のための製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011518881A JP2011518881A (ja) | 2011-06-30 |
JP2011518881A5 true JP2011518881A5 (ja) | 2012-05-10 |
Family
ID=41255303
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011507418A Pending JP2011518881A (ja) | 2008-04-28 | 2009-04-24 | 片頭痛の治療のための製剤 |
JP2014020406A Expired - Fee Related JP5943948B2 (ja) | 2008-04-28 | 2014-02-05 | 片頭痛の治療のための製剤 |
JP2015054395A Pending JP2015178496A (ja) | 2008-04-28 | 2015-03-18 | 片頭痛の治療のための製剤 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014020406A Expired - Fee Related JP5943948B2 (ja) | 2008-04-28 | 2014-02-05 | 片頭痛の治療のための製剤 |
JP2015054395A Pending JP2015178496A (ja) | 2008-04-28 | 2015-03-18 | 片頭痛の治療のための製剤 |
Country Status (8)
Country | Link |
---|---|
US (5) | US20110118189A1 (ja) |
EP (4) | EP2756756B1 (ja) |
JP (3) | JP2011518881A (ja) |
CN (2) | CN103550847A (ja) |
AU (1) | AU2009241847B2 (ja) |
CA (1) | CA2722743A1 (ja) |
ES (3) | ES2563061T3 (ja) |
WO (1) | WO2009134336A1 (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2124556B1 (en) | 2006-10-09 | 2014-09-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
CN104188907A (zh) | 2007-02-11 | 2014-12-10 | Map药物公司 | 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法 |
CA3066426A1 (en) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
US20110082150A1 (en) * | 2008-02-11 | 2011-04-07 | Robert Owen Cook | Headache pre-emption by dihydroergotamine treatment during headache Precursor events |
US8372432B2 (en) * | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CA2720108C (en) * | 2008-03-11 | 2016-06-07 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
AU2013202680C1 (en) * | 2008-04-28 | 2016-06-23 | Zogenix, Inc. | Novel formulations for treatment of migraine |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
UA108475C2 (uk) | 2009-07-31 | 2015-05-12 | Санофі-Авентіс Дойчланд Гмбх | Композиція інсуліну тривалої дії |
EP3782649A1 (en) * | 2009-07-31 | 2021-02-24 | Ascendis Pharma A/S | Biodegradable polyethylene glycol based water-insoluble hydrogels |
MX2012001399A (es) | 2009-07-31 | 2012-03-21 | Sanofi Aventis Deutschland | Profarmacos que comprenden un conjugado de insulina-conector. |
WO2011026125A2 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
MX353096B (es) | 2010-08-19 | 2017-12-19 | Buck Institute For Age Res Star | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US20140073678A1 (en) * | 2012-09-12 | 2014-03-13 | Monosol Rx, Llc | Anti-pain and anti-nausea and/or vomiting combinatorial compositions |
NZ629475A (en) | 2012-09-28 | 2017-03-31 | St Renatus Llc | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines |
CN103040721B (zh) * | 2012-12-17 | 2014-07-02 | 海南圣欣医药科技有限公司 | 一种甲磺酸多拉司琼脂质体注射剂 |
AU2013361337A1 (en) | 2012-12-21 | 2015-07-09 | Map Pharmaceuticals, Inc. | 8'-Hydroxy-Dihydroergotamine compounds and compositions |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
WO2016066864A1 (es) | 2014-10-30 | 2016-05-06 | Innovaciones Fisicas Y Quimicas Sostenibles, S.L. | Nanopartículas para la liberación controlada de ingredientes activos |
CN104800191A (zh) * | 2015-05-04 | 2015-07-29 | 徐俊 | 佐米曲普坦纳米冻干粉及其制备方法 |
CA2991108A1 (en) | 2015-07-02 | 2017-01-05 | Civitas Therapeutics, Inc. | Triptan powders for pulmonary delivery |
US20170119738A1 (en) | 2015-10-28 | 2017-05-04 | Dr. Reddy's Laboratories, Ltd. | Pharmaceutical compositions for rizatriptan |
US20220233698A1 (en) * | 2015-11-25 | 2022-07-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
US9918932B2 (en) | 2016-02-19 | 2018-03-20 | Zosano Pharma Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines |
JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | 医薬組成物 |
CN107397721B (zh) * | 2016-05-18 | 2019-01-22 | 中国医学科学院基础医学研究所 | 含有布比卡因的药物组合物及其制备方法和用途 |
CA3027368A1 (en) | 2016-06-13 | 2017-12-21 | Ascendia Pharmaceuticals, Llc | Parenteral sustained-release delivery of carvedilol disperse systems |
US11660264B2 (en) | 2017-08-23 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
CN107648226A (zh) * | 2017-11-08 | 2018-02-02 | 莫玉艳 | 一种治疗偏头痛的药物组合物及其制备方法 |
US11660265B2 (en) | 2018-06-28 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
US11857520B2 (en) | 2018-12-19 | 2024-01-02 | Nortic Holdings Inc. | Therapeutic composition of intranasal lidocaine |
KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
CN115500876A (zh) * | 2019-12-27 | 2022-12-23 | 四川大学华西医院 | 治疗卵圆孔未闭的装置在制备治疗癫痫和/或偏头痛的装置中的用途 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3859996A (en) | 1973-07-18 | 1975-01-14 | Mizzy Inc | Multi-dose injector |
DE2848503C2 (de) | 1978-11-08 | 1983-05-05 | Alcan Aluminiumwerk Nürnberg GmbH, 6000 Frankfurt | Maschinengehäuse mit einem eine relativ geringe Wandstärke aufweisenden Bauteil |
US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
US4421508A (en) | 1981-02-24 | 1983-12-20 | Cohen Edgar C | Vacuum-compression injector |
DE3115376A1 (de) | 1981-04-16 | 1982-12-16 | Hoechst Ag, 6000 Frankfurt | Nadelloses injektionsgeraet |
DE3115375A1 (de) | 1981-04-16 | 1982-11-11 | Hoechst Ag, 6000 Frankfurt | Kolbenpumpe fuer nadellose injektionsgeraete |
DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
US4507466A (en) | 1983-01-07 | 1985-03-26 | The Dow Chemical Corporation | Dense star polymers having core, core branches, terminal groups |
HU186718B (en) * | 1983-06-29 | 1985-09-30 | Radelkis Electrokemiai | Automatic needleless syringe operable by cardox cylinder suitable for personal giving injection e.g. insulin |
GB8416234D0 (en) | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
EP0271180B2 (en) | 1986-08-18 | 1997-06-18 | The Dow Chemical Company | Starburst conjugates |
US4913699A (en) | 1988-03-14 | 1990-04-03 | Parsons James S | Disposable needleless injection system |
JPH0284962A (ja) | 1988-06-14 | 1990-03-26 | Vci Corp | 負圧圧着無針注射器 |
US4957998A (en) | 1988-08-22 | 1990-09-18 | Pharmaceutical Delivery Systems, Inc. | Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
AU6550990A (en) | 1989-11-09 | 1991-05-16 | Bioject, Inc. | Needleless hypodermic injection device |
CA2095858A1 (en) | 1990-11-09 | 1992-05-10 | Peter Elliott Rosenzweig | Needleless hypodermic jet injector device |
US5176907A (en) | 1991-08-13 | 1993-01-05 | The Johns Hopkins University School Of Medicine | Biocompatible and biodegradable poly (phosphoester-urethanes) |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
DE69222006T2 (de) * | 1991-10-30 | 1998-01-22 | Glaxo Group Ltd | Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5367051A (en) | 1993-07-22 | 1994-11-22 | Sri International | Amine-containing polymerizable monomers and polymers functionalized with fullerenes to provide polymers with high temperature stability |
JP3487856B2 (ja) * | 1993-07-31 | 2004-01-19 | ウェストン メディカル リミテッド | 無針注射器 |
DE69533569T2 (de) | 1994-03-07 | 2006-01-05 | Dendritic Nanotechnologies, Inc., Mt. Pleasant | Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material |
SE518578C2 (sv) | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
GB9425642D0 (en) | 1994-12-20 | 1995-02-22 | Weston Medical Ltd | Filling device |
GB9504878D0 (en) | 1995-03-10 | 1995-04-26 | Weston Medical Ltd | Viscously coupled actuator |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
DE19526019A1 (de) | 1995-07-17 | 1997-01-23 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Kopfschmerzen |
GB9525757D0 (en) * | 1995-12-16 | 1996-02-14 | Weston Medical Ltd | Needleless injector drug capsule and filling method |
US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
GB9602605D0 (en) * | 1996-02-09 | 1996-04-10 | Weston Medical Ltd | Injection aid |
HUP9902128A3 (en) * | 1996-04-02 | 2000-01-28 | Weston Medical Ltd Eye | Method filling a drug capsule and article produced thereby |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US6586458B1 (en) | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
US5980948A (en) | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
NL1004059C2 (nl) * | 1996-09-18 | 1998-03-19 | Plastic Moulding Appliances B | Samenstel van houder en breeksluiting en werkwijze voor de vervaardiging daarvan. |
EP0932424B1 (en) | 1996-09-25 | 2002-06-19 | Weston Medical Limited | Method and apparatus for making an article from a formable material |
DE69735688T2 (de) | 1996-11-19 | 2007-04-05 | Octoplus B.V. | Mikropartikel mit gesteuerter Freisetzung |
EP0842657A1 (en) | 1996-11-19 | 1998-05-20 | OctoPlus B.V. | Microspheres for controlled release and processes to prepare these microspheres |
US6258059B1 (en) | 1997-02-06 | 2001-07-10 | Weston Medical Limited | Injection aid |
US6179583B1 (en) | 1997-02-25 | 2001-01-30 | Weston Medical Limited | Metered fluid delivery device |
US5911703A (en) | 1997-05-22 | 1999-06-15 | Avant Drug Delivery Systems, Inc. | Two-stage fluid medicament jet injector |
US6117949A (en) * | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
DE19807535A1 (de) | 1998-02-21 | 1999-08-26 | Asta Medica Ag | Pharmazeutische Kombinationen mit Tramadol |
AU752225B2 (en) | 1998-07-17 | 2002-09-12 | Pacira Pharmaceuticals, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
GB9818110D0 (en) * | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
WO2000021536A1 (en) | 1999-10-12 | 2000-04-20 | Sheftell Fred D | Prevention and treatment of migraine and other recurrent headaches using leukotriene ltd4 receptor blocker drugs |
AU3596500A (en) | 1999-02-19 | 2000-09-04 | Pozen, Inc. | Formulation of 5-ht agonists with cox-2 inhibitors |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
AU1249001A (en) | 1999-06-11 | 2001-01-31 | Nektar Therapeutics Al, Corporation | Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers |
WO2001007505A1 (en) | 1999-07-21 | 2001-02-01 | The Penn State Research Foundation | Polyphosphazene polymers |
ITFO990015A1 (it) | 1999-07-23 | 2001-01-23 | Verdini Antonio | "dendrimeri polipeptidici quali trasportatori unimolecolari di farmaci e sostanze biologicamente attive". |
GB9918425D0 (en) * | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
US6319224B1 (en) * | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
DE19954843C2 (de) | 1999-11-09 | 2003-11-20 | Novosom Ag | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung |
DE60024491T2 (de) * | 1999-12-01 | 2006-08-10 | Natco Pharma Ltd., Banjara Hills | Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050042194A1 (en) * | 2000-05-11 | 2005-02-24 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US20020076443A1 (en) * | 2000-06-19 | 2002-06-20 | Stanley Stein | Multiple phase cross-linked compositions and uses thereof |
US20020077328A1 (en) * | 2000-07-13 | 2002-06-20 | Fred Hassan | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain |
AU2001285156A1 (en) | 2000-08-23 | 2002-03-04 | Bristol-Myers Squibb Company | Combination therapy for the treatment of migraine |
CA2419623A1 (en) | 2000-08-30 | 2002-03-07 | Lilly Icos Llc | Method for treatment of migraine using pde5 inhibitors |
EP1184032A1 (en) | 2000-08-31 | 2002-03-06 | OctoPlus B.V. | Dextran hydrogels |
EP1395626A1 (en) | 2001-05-11 | 2004-03-10 | AP Pharma, Inc. | Peg-poe, peg-poe-peg, and poe-peg-poe block copolymers |
GB2404865B (en) * | 2001-09-11 | 2005-09-28 | Caretek Medical Ltd | Novel drug delivery technology |
US6524606B1 (en) | 2001-11-16 | 2003-02-25 | Ap Pharma, Inc. | Bioerodible polyorthoesters containing amine groups |
AU2003243875B2 (en) * | 2002-07-11 | 2006-07-06 | Tecpharma Licensing Ag | Needle-free injection device |
DE10393729T5 (de) * | 2002-11-15 | 2005-10-13 | Helsinn Healthcare S.A. | Verfahren zur Behandlung von Emesis |
CA2510465A1 (en) * | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
SI1575566T1 (sl) * | 2002-12-26 | 2012-08-31 | Pozen Inc | Veäśplastna dozirna oblika vsebujoäśa naproksen in triptane |
GB2398071B (en) * | 2003-01-24 | 2006-06-07 | Synthon Bv | Process for making ondansetron and intermediate thereof |
US20040162333A1 (en) * | 2003-02-19 | 2004-08-19 | Naima Mezaache | Rapid absorption selective 5-HT agonist formulations |
US20040192781A1 (en) * | 2003-03-31 | 2004-09-30 | Haley Eugene T. | Method of administration for metoclopramide and pharmaceutical formulation therefor |
EP1644004A4 (en) * | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS |
EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
US20050256182A1 (en) * | 2004-05-11 | 2005-11-17 | Sutter Diane E | Formulations of anti-pain agents and methods of using the same |
US20060040895A1 (en) * | 2004-08-19 | 2006-02-23 | Kipling Thacker | Aesthetic use of hyaluronan |
US20060240043A1 (en) * | 2004-10-08 | 2006-10-26 | Meyerson Laurence R | Methods and compositions for treating migraine pain |
US20080039387A1 (en) * | 2004-11-04 | 2008-02-14 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
US20090232898A1 (en) * | 2005-03-28 | 2009-09-17 | Anders Pettersson | Pharmaceutical Compositions Useful in the Treatment of Migraine |
US8998881B2 (en) * | 2005-08-10 | 2015-04-07 | Alza Corporation | Method for delivering drugs to tissue under microjet propulsion |
EP3058972A1 (en) * | 2005-11-17 | 2016-08-24 | Zogenix, Inc. | Delivery of viscous formulations by needle-free injection |
WO2007103113A2 (en) | 2006-03-06 | 2007-09-13 | Pozen Inc. | Dosage forms for administering combinations of drugs |
BRPI0709965C1 (pt) * | 2006-04-13 | 2011-12-20 | Nupathe Inc | farmacocinética da administração iontoforética de sumatriptano |
US9144648B2 (en) * | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
US20080033755A1 (en) * | 2006-06-07 | 2008-02-07 | Krusz John C | Medical treatment modality for headache, pain, and other medical disorders |
-
2009
- 2009-04-24 AU AU2009241847A patent/AU2009241847B2/en not_active Ceased
- 2009-04-24 EP EP14165112.5A patent/EP2756756B1/en not_active Not-in-force
- 2009-04-24 ES ES14165112.5T patent/ES2563061T3/es active Active
- 2009-04-24 EP EP09739139.5A patent/EP2273880B1/en not_active Not-in-force
- 2009-04-24 WO PCT/US2009/002533 patent/WO2009134336A1/en active Application Filing
- 2009-04-24 EP EP15193827.1A patent/EP3000462A1/en not_active Withdrawn
- 2009-04-24 CA CA2722743A patent/CA2722743A1/en not_active Abandoned
- 2009-04-24 US US12/937,355 patent/US20110118189A1/en not_active Abandoned
- 2009-04-24 ES ES14181930.0T patent/ES2604968T3/es active Active
- 2009-04-24 CN CN201310399785.XA patent/CN103550847A/zh active Pending
- 2009-04-24 ES ES09739139.5T patent/ES2527448T3/es active Active
- 2009-04-24 CN CN2009801148840A patent/CN102014625A/zh active Pending
- 2009-04-24 EP EP14181930.0A patent/EP2829265B1/en not_active Not-in-force
- 2009-04-24 JP JP2011507418A patent/JP2011518881A/ja active Pending
-
2013
- 2013-04-16 US US13/863,686 patent/US20130231311A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/170,318 patent/US20140148485A1/en not_active Abandoned
- 2014-02-05 JP JP2014020406A patent/JP5943948B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-18 JP JP2015054395A patent/JP2015178496A/ja active Pending
- 2015-11-03 US US14/930,982 patent/US20160051466A1/en not_active Abandoned
-
2016
- 2016-02-04 US US15/015,713 patent/US20160151571A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011518881A5 (ja) | ||
JP6200648B2 (ja) | 三叉神経・自律神経性頭痛、片頭痛、および血管症状の治療および予防のための組成物 | |
JP6588934B2 (ja) | 薬学的組成物 | |
RU2670750C9 (ru) | Композиции для местного применения и способы лечения локальных нарушений | |
ES2604968T3 (es) | Nuevas formulaciones para el tratamiento de la migraña | |
Camu et al. | Pharmacology of systemic analgesics | |
Gavva et al. | Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans | |
JP6139743B2 (ja) | ロキソプロフェン含有医薬組成物 | |
ES2608006T3 (es) | Preparación farmacéutica que contiene oxicodona y naloxona | |
BRPI0721940A2 (pt) | Formulações de analgésicos opióides confinados e não-opióides | |
JP2002529499A (ja) | 痛みの治療方法 | |
JP2008528566A (ja) | 鎮痛薬組成物 | |
EP2726105A1 (en) | A new stable anesthetic composition for reducing skin reactions | |
Beckman | Pathophysiology and management of surgical and chronic oral pain in dogs and cats | |
US10966946B2 (en) | Compounded compositions and methods for treating pain | |
NL1024816C2 (nl) | Met kleefstof bekleed vel voor dermale aflevering van een selectieve cyclooxygenase-2-remmer. | |
US20220001158A1 (en) | Thermally regulated transdermal drug delivery system | |
WO2006025516A1 (ja) | ペロスピロン経皮投与用医薬組成物 | |
EP1806151B1 (en) | Drug for external use and adhesive patch | |
JP2005047906A (ja) | 外用消炎鎮痛剤組成物 | |
AR052138A1 (es) | Composicion farmaceutica de liberacion lenta que comprende (+)-(2s,3s)-2-(3-clorofenil)-3,5,5-trimetil-2- morfolinol y su uso para la elaboracion de un medicamento | |
Bennett et al. | Dexmedetomidine or medetomidine: which should veterinary surgeons select? | |
Kashlan et al. | Pain management in dermatologic procedures: before and after | |
Schwartz | Perioperative pain management | |
US20090247537A1 (en) | Methods for preventing or treating bruxism using dopaminergic agents |